Biliary Cirrhosis - Pipeline Review, H2 2015

Date: July 29, 2015
Pages: 82
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BA03763ABF7EN
Leaflet:

Download PDF Leaflet

Biliary Cirrhosis - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Biliary Cirrhosis - Pipeline Review, H2 2015’, provides an overview of the Biliary Cirrhosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Biliary Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Biliary Cirrhosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Biliary Cirrhosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Biliary Cirrhosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Biliary Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Biliary Cirrhosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Biliary Cirrhosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Biliary Cirrhosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Biliary Cirrhosis Overview
Therapeutics Development
Pipeline Products for Biliary Cirrhosis - Overview
Pipeline Products for Biliary Cirrhosis - Comparative Analysis
Biliary Cirrhosis - Therapeutics under Development by Companies
Biliary Cirrhosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Biliary Cirrhosis - Products under Development by Companies
Biliary Cirrhosis - Companies Involved in Therapeutics Development
AlbireoPharma
CymaBay Therapeutics, Inc.
Dr. Falk Pharma GmbH
Enanta Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Intercept Pharmaceuticals, Inc.
Johnson & Johnson
MediGene AG
NGM Biopharmaceuticals, Inc.
Shire Plc
Virobay Inc.
Biliary Cirrhosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FFP-104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2330672 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MBX-8025 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
obeticholic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RhuDex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SHP-625 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize Farnesoid X Receptor for Non-alcoholic Steatohepatitis and Primary Biliary Cirrhosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ustekinumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VBY-825 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biliary Cirrhosis - Recent Pipeline Updates
Biliary Cirrhosis - Dormant Projects
Biliary Cirrhosis - Product Development Milestones
Featured News & Press Releases
Jun 29, 2015: Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for Marketing Approval of Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
Apr 13, 2015: Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015
Mar 24, 2015: NGM Biopharmaceuticals Announces Positive Phase 2 Clinical Data in Primary Biliary Cirrhosis Patients for NGM282, a First-in-Class Investigational Medicine
Feb 05, 2015: Initiation of a Phase II Trial for A4250, the Company’s Lead Compound for Cholestatic Liver Diseases and NASH
Nov 08, 2014: Intercept Announces Additional Data for OCA in Primary Biliary Cirrhosis
May 28, 2014: Intercept Announces that FDA Grants Fast Track Designation to Obeticholic Acid for the Treatment of Patients with Primary Biliary Cirrhosis
Apr 12, 2014: Intercept Reports Additional Positive Data From POISE Trial at EASL Late-Breaker Session
Apr 11, 2014: Intercept Announces Preclinical Data Demonstrating OCA's Potential Role in Preventing Complications of Cirrhosis
Apr 04, 2014: Data From Intercept's Pivotal Phase 3 POISE Trial of Its FXR Agonist Obeticholic Acid to Treat Primary Biliary Cirrhosis and Other Key Obeticholic Acid Data to be Presented at EASL 2014
Mar 16, 2014: Intercept Announces Positive Pivotal Phase 3 POISE Trial Results
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Biliary Cirrhosis, H2 2015
Number of Products under Development for Biliary Cirrhosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Biliary Cirrhosis - Pipeline by AlbireoPharma, H2 2015
Biliary Cirrhosis - Pipeline by CymaBay Therapeutics, Inc., H2 2015
Biliary Cirrhosis - Pipeline by Dr. Falk Pharma GmbH, H2 2015
Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals, Inc., H2 2015
Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H2 2015
Biliary Cirrhosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015
Biliary Cirrhosis - Pipeline by Johnson & Johnson, H2 2015
Biliary Cirrhosis - Pipeline by MediGene AG, H2 2015
Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals, Inc., H2 2015
Biliary Cirrhosis - Pipeline by Shire Plc, H2 2015
Biliary Cirrhosis - Pipeline by Virobay Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Biliary Cirrhosis Therapeutics - Recent Pipeline Updates, H2 2015
Biliary Cirrhosis - Dormant Projects, H2 2015

LIST OF FIGURES

Number of Products under Development for Biliary Cirrhosis, H2 2015
Number of Products under Development for Biliary Cirrhosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

AlbireoPharma
CymaBay Therapeutics, Inc.
Dr. Falk Pharma GmbH
Enanta Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Intercept Pharmaceuticals, Inc.
Johnson & Johnson
MediGene AG
NGM Biopharmaceuticals, Inc.
Shire Plc
Virobay Inc.
Skip to top


Primary Biliary Cirrhosis - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 90 pages

Ask Your Question

Biliary Cirrhosis - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: